Prosecution Insights
Prosecution Insights
6 pending office actions • 4 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (17%) |
| Double-patenting only | 2 (33%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRISTOL, LYNN ANNE | 2 | 63.6% | +39.7% |
| MOSELEY II, NELSON B | 1 | 67.8% | +41.6% |
| BUNNER, BRIDGET E | 1 | 64.4% | +20.0% |
| YU, MISOOK | 1 | 38.9% | +17.7% |
| LUNDE, GRACE HENRY | 1 | 63.0% | +38.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17787793 | Therapy for the Treatment of Cancer | LUNDE, GRACE HENRY | 34d |
| 18484921 | MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | BRISTOL, LYNN ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18320599 | TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | BRISTOL, LYNN ANNE | 23d overdue |
| 18178783 | COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF | BUNNER, BRIDGET E | 28d |
| 17787793 | Therapy for the Treatment of Cancer | LUNDE, GRACE HENRY | 34d |
| 18484921 | MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | BRISTOL, LYNN ANNE | — |
| 18321354 | Variant CD3-Binding Domains and Their Use in Combination Therapies for the Treatment of Disease | MOSELEY II, NELSON B | — |
| 18006294 | METHODS FOR THE USE OF A PD-1 X CTLA-4 BISPECIFIC MOLECULE | YU, MISOOK | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1641 | 2 |
| 1642 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18484921 | MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | BRISTOL, LYNN ANNE | 1643 | §103§112Other | Non-Final OA | — | Pending | Oct 11, 2023 |
| 18321354 | Variant CD3-Binding Domains and Their Use in Combination Therapies for the Treatment of Disease | MOSELEY II, NELSON B | 1642 | DP | Non-Final OA | — | Pending | May 22, 2023 |
| 18320599 | TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | BRISTOL, LYNN ANNE | 1643 | DP | Final Rejection | 23d overdue | Pending | May 19, 2023 |
| 18178783 | COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF | BUNNER, BRIDGET E | 1647 | §112Other | Non-Final OA | 28d | Pending | Mar 06, 2023 |
| 18006294 | METHODS FOR THE USE OF A PD-1 X CTLA-4 BISPECIFIC MOLECULE | YU, MISOOK | 1641 | §102§103§112DPOther | Non-Final OA | — | Pending | Jan 20, 2023 |
| 17787793 | Therapy for the Treatment of Cancer | LUNDE, GRACE HENRY | 1641 | §103§112Other | Final Rejection | 34d | Pending | Jun 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial